Shares of Zafgen Inc (NASDAQ:ZFGN) have received an average recommendation of “Hold” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $8.10.
A number of research analysts recently issued reports on the company. Piper Jaffray Companies reduced their price objective on Zafgen from $6.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, May 30th. ValuEngine upgraded Zafgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered Zafgen from a “buy” rating to a “hold” rating in a research report on Saturday, July 20th. Roth Capital assumed coverage on Zafgen in a research report on Friday, April 26th. They set a “buy” rating and a $8.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and set a $6.00 price objective on shares of Zafgen in a research report on Monday.
A number of hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its holdings in shares of Zafgen by 150.8% in the 2nd quarter. Morgan Stanley now owns 184,606 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 110,989 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of Zafgen in the 2nd quarter worth approximately $163,000. Worth Venture Partners LLC acquired a new position in shares of Zafgen in the 2nd quarter worth approximately $316,000. A.R.T. Advisors LLC acquired a new position in shares of Zafgen in the 2nd quarter worth approximately $35,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Zafgen by 165.3% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 177,540 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 110,610 shares in the last quarter. Institutional investors own 82.89% of the company’s stock.
Shares of NASDAQ ZFGN traded down $0.06 during trading on Wednesday, reaching $0.88. The stock had a trading volume of 224,758 shares, compared to its average volume of 309,875. Zafgen has a one year low of $0.84 and a one year high of $12.35. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $33.36 million, a PE ratio of -0.46 and a beta of -0.46. The stock has a 50 day simple moving average of $1.09.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.06. On average, sell-side analysts expect that Zafgen will post -1.29 earnings per share for the current year.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Further Reading: Why are percentage decliners important?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.